Hjem › Eggstokkreft › Virginia
Kliniske studier for Eggstokkreft i Virginia
57 studier for Eggstokkreft søker deltakere på steder i Virginia.
Byer i Virginia
Offisiell studietekst (engelsk)
The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- og 5 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06995898Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Ballad Health Cancer Care - Bristol, Bristol
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- og 5 flere
RekruttererFase 2
Alle aldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564377Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Fairfax
RekruttererFase 1/2
Alder 18 til 130 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05797168A Study of PHST001 in Advanced Solid Tumors
- NEXT Oncology - Virginia, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- University of Virginia, Charlottesville
- NEXT Virginia, Fairfax
RekruttererFase 1
Alder 19 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06586957A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Next Virginia /ID# 279684, Fairfax
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 1. okt. 2026 · NCT07024784A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07814248A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Next Virginia /ID# 278607, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT07278336Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Virginia Commonwealth University/ Massey Cancer Center, Richmond
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT05051722First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
- NEXT Virginia, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT06799065A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- UVA Health University Hospital /ID# 275309, Charlottesville
- Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456, Fairfax
- Virginia Oncology Associates- Norfolk (Brock) /ID# 275227, Norfolk
- og 1 flere
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0295 - Virginia Oncology Associates, Chesapeake
- Site 0322 - Inova Schar Cancer Institute, Fairfax
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 29. sep. 2026 · NCT05128825Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Virginia Commonwealth University, Richmond
RekruttererFase 1/2
Alder 18 og eldre · Kvinner · Oppdatert 25. sep. 2026 · NCT03564340Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Virginia Cancer Specialists (VCS) ( Site 8012), Fairfax
- Virginia Oncology Associates (VOA) ( Site 8013), Norfolk
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 17. sep. 2026 · NCT07318558A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- NEXT Oncology, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07109726Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- University of Virginia Health System, Charlottesville
- Inova Schar Cancer Institute, Fairfax
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 15. sep. 2026 · NCT07214779A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Virginia Cancer Specialists, Fairfax
- Carilion Clinic, Roanoke
RekruttererFase 2
Alder 18 til 99 · Kvinner · Oppdatert 15. sep. 2026 · NCT07023627FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Inova Schar Cancer Institute, Fairfax
- Next Oncology Virginia, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06303505Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 10. sep. 2026 · NCT06293898Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- NEXT Oncology, Fairfax
RekruttererFase 1
Alder 18 og eldre · Kvinner · Oppdatert 3. sep. 2026 · NCT07755436A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Virginia Cancer Specialists (VCS) ( Site 8011), Fairfax
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 3. sep. 2026 · NCT06824467Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- University of Virginia, Charlottesville
RekruttererFase 1
Alder 15 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT06276491A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Inova Schar Cancer Institute, Falls Church
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. aug. 2026 · NCT06774963A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07182149A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- University of Virginia Cancer Center, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- og 5 flere
Rekrutterer
Alder 35 til 50 · Kvinner · Oppdatert 7. aug. 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- University of Virginia Cancer Center, Charlottesville
- VCU Massey Comprehensive Cancer Center, Richmond
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT06580314A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT06330064Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- NEXT Oncology - Virginia Cancer Specialists, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. aug. 2026 · NCT07444814Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Virginia Cancer Specialists, Fairfax
- USOR Virginia Oncology Associates, Norfolk
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 4. aug. 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Virginia Cancer Specialists, Fairfax
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jul. 2026 · NCT04657068A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- University of Virginia Comprehensive Cancer Center, Charlottesville
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. jul. 2026 · NCT06161025Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
- NEXT Virginia, Fairfax
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT07524322Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 522, Fairfax
- 300, Norfolk
RekruttererFase 2
Alder 18 og eldre · Kvinner · Oppdatert 16. jul. 2026 · NCT06906341Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
- Riverside Health, Newport News
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 14. jul. 2026 · NCT05804370Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.